Dual targeting of both innate and adaptive checkpoints is theoretically attractive, also since data suggest that dual targeting of discrete checkpoints, e.g. CD47, PD1/PD-L1 or CTLA4, can be synergistic with regard to their anti-tumor effects13,27,29. The gene discussed is CD47; the disease is neoplasm.